Drugs / AZD0328
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00752830 | Sep → Oct 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00738959 | Jun → Oct 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00687141 | Nov 2007 → Jun 2008 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04810104 | Oct 2022 → Jan 2024 | Parkinson disease, cognitive impairment with or without cerebellar ataxia | King's College London | Withdrawn | No outcome recorded |
| Phase 2 | NCT00669903 | Apr → Nov 2008 | schizophrenia | AstraZeneca | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0328 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00738959 ↗ |
| Action | Activate | “Neuronal acetylcholine receptor protein alpha-7 subunit agonist” CHEMBL2151437 ↗1“AZD0328 is a selective α7 nicotinic receptor agonist” NCT04810104 ↗ |
| Modality | Small molecule | — CHEMBL2151437 ↗ |
| Route | Oral | “Oral Multiple Ascending Doses of AZD0328” NCT00669903 ↗ |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit agonist” CHEMBL2151437 ↗ |